Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus

Comparison of the Immunogenicity and Safety of the Conventional Subunit, MF59-Adjuvanted, and Intradermal Influenza Vaccines in the Elderly

(2014) Yu Bin Seo et al.   Clinical and Vaccine Immunology

Current advancements and potential strategies in the development of MERS-CoV vaccines

(2014) Naru Zhang et al.   Expert Review of Vaccines

Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection

(2014) L. Du et al.   JOURNAL OF IMMUNOLOGY

A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein

(2014) L. Du et al.   JOURNAL OF VIROLOGY

Calling for rapid development of a safe and effective MERS vaccine

(2014) Peter J. Hotez et al.   MICROBES AND INFECTION

Evidence for Camel-to-Human Transmission of MERS Coronavirus

(2014) Esam I. Azhar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid generation of a mouse model for Middle East respiratory syndrome

(2014) Jincun Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus

(2014) Y. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design

(2014) Cuiqing Ma et al.   VACCINE

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines

(2014) Cuiqing Ma et al.   VACCINE

Detection of the Middle East Respiratory Syndrome Coronavirus Genome in an Air Sample Originating from a Camel Barn Owned by an Infected Patient

(2014) E. I. Azhar et al.   mBio

Middle East Respiratory Syndrome Coronavirus Quasispecies That Include Homologues of Human Isolates Revealed through Whole-Genome Analysis and Virus Cultured from Dromedary Camels in Saudi Arabia

(2014) T. Briese et al.   mBio

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

(2013) Odile Launay et al.   BMC INFECTIOUS DISEASES

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

(2013) Nianshuang Wang et al.   CELL RESEARCH

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants

(2013) Christopher B Fox et al.   Expert Review of Vaccines

Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine

(2013) Harshad P. Patil et al.   JOURNAL OF CONTROLLED RELEASE

Bilateral Entry and Release of Middle East Respiratory Syndrome Coronavirus Induces Profound Apoptosis of Human Bronchial Epithelial Cells

(2013) X. Tao et al.   JOURNAL OF VIROLOGY

The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies

(2013) H. Mou et al.   JOURNAL OF VIROLOGY

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread

(2013) Lu Lu et al.   MICROBES AND INFECTION

Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice

(2013) G Pineton de Chambrun et al.   Mucosal Immunology

Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26

(2013) Guangwen Lu et al.   NATURE

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

(2013) V. Stalin Raj et al.   NATURE

A Critical HA1 Neutralizing Domain of H5N1 Influenza in an Optimal Conformation Induces Strong Cross-Protection

(2013) Lanying Du et al.   PLoS One

Mucosal and Systemic Immune Responses to Mycobacterium tuberculosis Antigen 85A following Its Co-Delivery with CpG, MPLA or LTB to the Lungs in Mice

(2013) Julie Todoroff et al.   PLoS One

A “Prime-Pull” Vaccine Strategy Has a Modest Effect on Local and Systemic Antibody Responses to HIV gp140 in Mice

(2013) John S. Tregoning et al.   PLoS One

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines

(2013) Lanying Du et al.   PLoS One

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study

(2013) Lynette Denny et al.   VACCINE

Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine

(2012) Jacob Atsmon et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

(2012) Ali M. Zaki et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Adjuvanticity of an O. volvulus-Derived rOv-ASP-1 Protein in Mice Using Sequential Vaccinations and in Non-Human Primates

(2012) Jing Wang et al.   PLoS One

The mechanism of action of MF59 – An innately attractive adjuvant formulation

(2012) D.T. O’Hagan et al.   VACCINE

Developments of subunit and VLP vaccines against influenza a virus

(2012) Ma-ping Deng et al.   VIROLOGICA SINICA

Immunogenicity and Safety of the Influenza A/H1N1 2009 Inactivated Split-Virus Vaccine in Young and Older Adults: MF59-Adjuvanted Vaccine versus Nonadjuvanted Vaccine

(2011) Hee Jin Cheong et al.   Clinical and Vaccine Immunology

A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers

(2011) Paul Spearman et al.   JOURNAL OF INFECTIOUS DISEASES

Evidence for a Common Evolutionary Origin of Coronavirus Spike Protein Receptor-Binding Subunits

(2011) F. Li   JOURNAL OF VIROLOGY

A Recombinant Vaccine of H5N1 HA1 Fused with Foldon and Human IgG Fc Induced Complete Cross-Clade Protection against Divergent H5N1 Viruses

(2011) Lanying Du et al.   PLoS One

Vaccine adjuvants – Current status and prospects on controlled release adjuvancity

(2011) S.M. Sivakumar et al.   SAUDI PHARMACEUTICAL JOURNAL

Mode of action of adjuvants: Implications for vaccine safety and design

(2010) Béatris Mastelic et al.   BIOLOGICALS

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

(2010) E. Fragapane et al.   Clinical and Vaccine Immunology

New adjuvants for human vaccines

(2010) M Lamine Mbow et al.   CURRENT OPINION IN IMMUNOLOGY

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

(2010) Paolo Durando et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Human IgG Subclasses: In Vitro Neutralization of and In Vivo Protection against West Nile Virus

(2010) Y. Hofmeister et al.   JOURNAL OF VIROLOGY

Delivery of foreign antigens by engineered outer membrane vesicle vaccines

(2010) D. J. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The immunobiology of aluminium adjuvants: how do they really work?

(2010) Christopher Exley et al.   TRENDS IN IMMUNOLOGY

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates

(2010) Filippo Ansaldi et al.   VACCINE

Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors

(2009) John C. Martyn et al.   ARCHIVES OF VIROLOGY

AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity

(2009) A. M. Didierlaurent et al.   JOURNAL OF IMMUNOLOGY

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity

(2009) Lanying Du et al.   VIROLOGY

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

(2008) A. S. De Groot et al.   BLOOD

Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant

(2008) C. R. Casella et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE